Bluesky Facebook Reddit Email

The multidimensional biology of SKP2: mechanisms, pathologies, and emerging therapeutic frontiers

04.09.26 | Compuscript Ltd

SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2025-0094

Announcing a new publication for Acta Materia Medica journal. S phase kinase-associated protein 2 (SKP2), the rate-limiting substrate receptor of the SKP1-Cullin1-F-box (SCF) E3 ubiquitin ligase complex, is considered a canonical gatekeeper of cell cycle progression. However, accumulating evidence indicates that SKP2 functions as a multifaceted signaling hub that orchestrates metabolic reprogramming, the DNA damage response, stem cell maintenance, and synaptic plasticity. Dysregulation of these processes contributes to the pathogenesis of many types of human diseases, including cancer. This review provides a comprehensive overview of the diverse biological roles of SKP2, beginning with detailed insights into the assembly and substrate-recognition mechanisms of the Cullin1-SKP2-CKS1 protein complex. Moreover, the functional dichotomy of SKP2 is explored, expanding its classic role in K48-linked proteasomal degradation to include noncanonical roles in K63-linked signaling activation. Furthermore, the pathogenic implications of SKP2 in malignancies such as castration-resistant prostate cancer (CRPC) and triple-negative breast cancer (TNBC) is elucidated, as well as neurodegenerative conditions, including Alzheimer’s disease. More importantly, the therapeutic approaches targeting SKP2, highlighting the shift from first-generation protein-protein interaction (PPI) inhibitors to next-generation degraders are evaluated, including the novel induced-proximity degrader SKPer1 and emerging PROTACs. Finally, to bridge the gap to clinical translation, the remaining druggability challenges and future directions for pharmacological optimization are discussed.

# # # # # #

Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.

Submission Process

Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed

Queries about the journal can be sent to editorialoffice@amm-journal.org .

Please visit https://amm-journal.org/ to learn more about the journal.

Editorial Board: https://amm-journal.org/index.php/editorial-board/

There are no author submission or article processing fees.

Follow Acta Materia Medica on Twitter https://twitter.com/AMM_journal ; Facebook ( https://www.facebook.com/AMMjournal )

eISSN 2737-7946

Tao Hou, Xiangmei Hua and Peiqiang Yan et al. The multidimensional biology of SKP2: mechanisms, pathologies, and emerging therapeutic frontiers. Acta Materia Medica. 2026. Vol. 5(1):113-143. DOI: 10.15212/AMM-2025-0094

10.15212/AMM-2025-0094

Keywords

Article Information

Contact Information

Conor Lovett
Compuscript Ltd
c.lovett@cvia-journal.org

How to Cite This Article

APA:
Compuscript Ltd. (2026, April 9). The multidimensional biology of SKP2: mechanisms, pathologies, and emerging therapeutic frontiers. Brightsurf News. https://www.brightsurf.com/news/1ZZG37D1/the-multidimensional-biology-of-skp2-mechanisms-pathologies-and-emerging-therapeutic-frontiers.html
MLA:
"The multidimensional biology of SKP2: mechanisms, pathologies, and emerging therapeutic frontiers." Brightsurf News, Apr. 9 2026, https://www.brightsurf.com/news/1ZZG37D1/the-multidimensional-biology-of-skp2-mechanisms-pathologies-and-emerging-therapeutic-frontiers.html.